A phase II study of idarubicin in the treatment of measurable gastric cancer.
Idarubicin is one of the new anthracycline analogues. It has a higher therapeutic index than either doxorubicin or daunorubicin in a variety of murine leukemias and solid tumors. The authors performed a multicenter Phase II trial of idarubicin in patients with advanced gastric cancer. Seventeen patients with measurable metastatic disease were entered into the trial and treated with idarubicin at a starting dose of 15 mg/m2. This dose was escalated or reduced according to toxicity. There were no documented responses. The dose-limiting toxicity was myelosuppression. These data did not compared favourably with the data on doxorubicin in the treatment of gastric carcinoma. A conclusion could not be reached on whether idarubicin has minimal activity in the treatment of gastric carcinoma.
MacCormick
R
R
Cancer Treatment and Research Foundation, Nova Scotia, Halifax, Canada.
Hirsch
G
G
Gupta
S
S
Shannon
P
P
Rotstein
L
L
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000368:Aged; D002170:Canada; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology
D015255:Idarubicin